Global Program Clinical Head News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Global program clinical head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Global Program Clinical Head Today - Breaking & Trending Today

DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics Announces Changes to Management

DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics Announces Changes to Management
Atriva Therapeutics Announces Changes to Management
13.04.2021 / 09:30
Atriva Therapeutics Announces Changes to Management
- Olaf Althaus appointed Chief Financial Officer
- Stephan Stenglein, M.D., recently joined as Chief Medical Officer
- Proven track record and 20+ years of experience in their respective fields of expertise
Tübingen (Germany), April 13, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management team. Olaf Althaus was appointed Chief Financial Officer, effective May 2020, while Stephan Stenglein, M.D., was named Chief Medical Officer, effective February 2021. ....

Frankfurt Am Main , Nordrhein Westfalen , City Of , United Kingdom , Eva Bauer Raimund Gabriel , Olaf Althaus , Stephan Stenglein , Kostenloser Wertpapierhandel , Gernot Rohde , Aeterna Zentaris Gmb , Rainer Lichtenberger , Mc Services , Global Program , Global Program Clinical Head , Centre Clinical Trial To Evaluate The Safety , Distribution Services , Stage Development Respiratory At Astrazeneca , Shire Plc , Goethe University Hospital , Karlsruhe University Diplom Wirtschaftsingenieurwesen , Vp Clinical Sciences At Glenmark Pharmaceuticals , Atriva Therapeutics Gmbh , Therapeutics Announces Changes , Chief Financial , Chief Medical , Therapeutics Gmbh ,

Transcenta Holding Announces Appointment of Dr. Michael Shi as Executive Vice President, Head of Global R&D and Chief Medical Officer

®/Jadenu
®, BGJ398, TKI258 (dovitinib) and PDR001. Most recently, he led the development teams to achieve accelerated approval of Tabrecta
® and Zykadia
® in sickle cell disease, all under the US FDA breakthrough therapy designation.
We are honored to have Dr. Shi joining the Transcenta team, said Dr. Xueming Qian, Co-Founder and CEO of Transcenta. As a seasoned biopharmaceutical industrial expert, Dr. Shi worked extensively in the areas of clinical development, translational medicine, biomarker development, and discovery research in several well-known companies. He will lead our global clinical development and registration of all therapeutic area products.
The biopharmaceutical industry has made great progress in China in recent years, said Dr. Shi. As an integrated biopharmaceutical company focusing on innovative biological products, Transcenta has great potential. I m very excited to join the company and look forward to accelerating the research ....

United States , New Jersey , East Hanover , Li Xu , Xueming Qian , Michael Shi , Union Medical College , Prnewswire Transcenta Holding Limited , University Of Michigan Medical School , Harvard Medical School , University Of Southern California , Holding Limited , Executive Vice President , Chief Medical , Chief Medical Officer , Global Program Clinical Head , Novartis Pharmaceuticals , Peking Union Medical College , Molecular Pharmacology , Southern California , Harvard Medical , Program Director , Genetics Variation , Michigan Medical , Transcenta Holding Limited , ஒன்றுபட்டது மாநிலங்களில் ,